Production (Stage)
Evofem Biosciences, Inc.
EVFM
$0.01
$0.00044.17%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -88.11% | 58.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -88.11% | 58.01% | |||
| Cost of Revenue | -75.86% | 73.99% | |||
| Gross Profit | -91.42% | 54.18% | |||
| SG&A Expenses | -55.88% | 107.12% | |||
| Depreciation & Amortization | -29.87% | 5.65% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -93.61% | 16.88% | |||
| Operating Income | 132.60% | 58.89% | |||
| Income Before Tax | 131.48% | -27.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 131.48% | -28.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 131.48% | -28.41% | |||
| EBIT | 132.60% | 58.89% | |||
| EBITDA | 181.76% | 68.12% | |||
| EPS Basic | 129.17% | -17.07% | |||
| Normalized Basic EPS | 129.61% | -24.31% | |||
| EPS Diluted | 100.66% | -22.36% | |||
| Normalized Diluted EPS | 100.56% | -24.31% | |||
| Average Basic Shares Outstanding | 7.16% | 9.67% | |||
| Average Diluted Shares Outstanding | 5,609.55% | 9.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||